The 30 day mortality is the key in this table. Protocols like FLAG-IDA or CLAG-M can get patients to a CR at reasonable rate, but at the cost of very high 30 day mortalities.
It is important to keep in mind that we will be seeing patients in this trial that have failed established treatments like FLAG-IDA. A treatment that might give an 80% response rate as a second line treatment, might only give a 30% response rate at third line treatment, and even lower as a fourth line or beyond. Each treatment failure makes the task of getting a patient to a CR exponentially more difficult.
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-51
-
- There are more pages in this discussion • 195 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |